Country: United States
Language: English
Source: NLM (National Library of Medicine)
OSELTAMIVIR PHOSPHATE (UNII: 4A3O49NGEZ) (OSELTAMIVIR ACID - UNII:K6106LV5Q8)
REMEDYREPACK INC.
OSELTAMIVIR PHOSPHATE
OSELTAMIVIR CARBOXYLATE 75 mg
ORAL
PRESCRIPTION DRUG
Oseltamivir Phosphate Capsules, USP are indicated for the treatment of acute, uncomplicated illness due to influenza A and B infection in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. Oseltamivir Phosphate Capsules, USP are indicated for the prophylaxis of influenza A and B in patients 1 year and older. - Oseltamivir Phosphate Capsules, USP are not a substitute for early influenza vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. - Influenza viruses change over time. Emergence of resistance substitutions could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Oseltamivir Phosphate Capsules, USP [ see Microbiology (12.4) ] - Oseltamivir Phosphate C
Oseltamivir Phosphate Capsules, USP 30-mg capsules (30 mg free base equivalent of the phosphate salt): Hard Gelatin, White Opaque/White Opaque Capsule, imprinted with black ink "N" on the body and black ink "1008" on the cap. Available in blister packages of 10 (NDC 70710-1008-2). 45-mg capsules (45 mg free base equivalent of the phosphate salt): Hard Gelatin, Light Blue Grey Opaque/ Light Blue Grey Opaque Capsule, imprinted with black ink "N" on the body and black ink "1009" on the cap. Available in blister packages of 10 (NDC 70710-1009-2). 75-mg capsules (75 mg free base equivalent of the phosphate salt): Hard Gelatin, White Opaque/ Light Blue Grey Opaque Capsule, imprinted with black ink "N" on the body and black ink "1010" on the cap. Available in blister packages of 10 (NDC 70710-1010-2). Storage Store the capsules at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature].
Abbreviated New Drug Application
OSELTAMIVIR PHOSPHATE- OSELTAMIVIR PHOSPHATE CAPSULE REMEDYREPACK INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE OSELTAMIVIR PHOSPHATE CAPSULES SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR OSELTAMIVIR PHOSPHATE CAPSULES. OSELTAMIVIR PHOSPHATE CAPSULES, FOR ORAL USE. INITIAL U.S. APPROVAL: 1999 RECENT MAJOR CHANGES Warnings and Precautions ( 5.2) 04/2018 INDICATIONS AND USAGE Oseltamivir Phosphate is an influenza neuraminidase inhibitor (NAI) indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2) Limitations of Use: Not a substitute for annual influenza vaccination. ( 1.3) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3) DOSAGE AND ADMINISTRATION Treatment of influenza ( 2.2) Adults and adolescents (13 years and older): 75 mg twice daily for 5 days Pediatric patients 1 to 12 years of age: Based on weight twice daily for 5 days Pediatric patients 2 weeks to less than 1 year of age: 3 mg/kg twice daily for 5 days Renally impaired adult patients (creatinine clearance >30-60 mL/min): Reduce to 30 mg twice daily for 5 days ( 2.4) Renally impaired adult patients (creatinine clearance >10-30 mL/min): Reduce to 30 mg once daily for 5 days ( 2.4) ESRD patients on hemodialysis: Reduce to 30 mg immediately and then 30 mg after every hemodialysis cycle. Treatment duration not to exceed 5 days ( 2.4) ESRD patients on CAPD: Reduce to a single 30 mg dose immediately ( 2.4) Prophylaxis of influenza ( 2.3) Adults and adolescents (13 years and older): 75 mg once daily for at least 10 days Community outbreak: 75 mg once daily for up to 6 weeks Pediatric patients 1 to 12 years of age: Based on weight Read the complete document